HC Wainwright Issues Negative Forecast for InflaRx Earnings

InflaRx N.V. (NASDAQ:IFRX) – Equities research analysts at HC Wainwright decreased their FY2025 earnings per share estimates for shares of InflaRx in a note issued to investors on Monday, November 10th. HC Wainwright analyst M. Keller now expects that the company will earn ($0.81) per share for the year, down from their prior estimate of ($0.73). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s FY2026 earnings at ($0.65) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at ($0.65) EPS.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million.

A number of other equities analysts have also recently issued reports on IFRX. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Tuesday. Wall Street Zen cut InflaRx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a report on Tuesday. Finally, Guggenheim increased their price objective on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.60.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.46 on Thursday. InflaRx has a one year low of $0.71 and a one year high of $2.82. The firm has a market capitalization of $98.01 million, a P/E ratio of -1.82 and a beta of 1.38. The company’s fifty day moving average is $1.38 and its two-hundred day moving average is $1.19.

Institutional Trading of InflaRx

A number of institutional investors and hedge funds have recently bought and sold shares of IFRX. DAFNA Capital Management LLC acquired a new stake in shares of InflaRx in the first quarter worth $459,000. Concurrent Investment Advisors LLC acquired a new stake in InflaRx in the second quarter valued at approximately $65,000. 683 Capital Management LLC grew its holdings in InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares in the last quarter. XTX Topco Ltd purchased a new position in InflaRx in the 1st quarter valued at about $38,000. Finally, Woodline Partners LP purchased a new position in InflaRx in the 1st quarter valued at about $766,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.